Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 57.72 Million SEK | 16.6% |
| 2022 | 49.5 Million SEK | -25.82% |
| 2021 | 66.73 Million SEK | 50.31% |
| 2020 | 44.39 Million SEK | 14.82% |
| 2019 | 38.66 Million SEK | -33.36% |
| 2018 | 58.02 Million SEK | 29.11% |
| 2017 | 44.93 Million SEK | 64.59% |
| 2016 | 27.3 Million SEK | 22.62% |
| 2015 | 22.26 Million SEK | -39.74% |
| 2014 | 36.95 Million SEK | 26.56% |
| 2013 | 29.19 Million SEK | 45.54% |
| 2012 | 20.06 Million SEK | 54.26% |
| 2011 | 13 Million SEK | 10.56% |
| 2010 | 11.76 Million SEK | 43.41% |
| 2009 | 8.2 Million SEK | 48.5% |
| 2008 | 5.52 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 59.16 Million SEK | 2.5% |
| 2024 Q3 | 68.48 Million SEK | 11.47% |
| 2024 Q2 | 61.43 Million SEK | 3.84% |
| 2023 Q1 | 40.49 Million SEK | -18.2% |
| 2023 Q4 | 57.72 Million SEK | -19.92% |
| 2023 FY | 57.72 Million SEK | 16.6% |
| 2023 Q3 | 72.08 Million SEK | 62.11% |
| 2023 Q2 | 44.46 Million SEK | 9.81% |
| 2022 Q1 | 55.32 Million SEK | -17.1% |
| 2022 Q4 | 49.5 Million SEK | -26.07% |
| 2022 Q3 | 66.96 Million SEK | 32.2% |
| 2022 FY | 49.5 Million SEK | -25.82% |
| 2022 Q2 | 50.65 Million SEK | -8.45% |
| 2021 Q1 | 47.89 Million SEK | 7.88% |
| 2021 Q3 | 82.96 Million SEK | -14.08% |
| 2021 Q4 | 66.73 Million SEK | -19.56% |
| 2021 FY | 66.73 Million SEK | 50.31% |
| 2021 Q2 | 96.56 Million SEK | 101.6% |
| 2020 Q3 | 56.4 Million SEK | -14.31% |
| 2020 FY | 44.39 Million SEK | 14.82% |
| 2020 Q1 | 76.25 Million SEK | 97.2% |
| 2020 Q2 | 65.81 Million SEK | -13.68% |
| 2020 Q4 | 44.39 Million SEK | -21.28% |
| 2019 FY | 38.66 Million SEK | -33.36% |
| 2019 Q2 | 59.53 Million SEK | 27.37% |
| 2019 Q3 | 48.57 Million SEK | -18.41% |
| 2019 Q4 | 38.66 Million SEK | -20.39% |
| 2019 Q1 | 46.73 Million SEK | -19.45% |
| 2018 Q1 | 38.28 Million SEK | -14.8% |
| 2018 Q4 | 58.02 Million SEK | -10.95% |
| 2018 Q3 | 65.15 Million SEK | -1.12% |
| 2018 Q2 | 65.89 Million SEK | 72.1% |
| 2018 FY | 58.02 Million SEK | 29.11% |
| 2017 Q2 | 35.4 Million SEK | -20.19% |
| 2017 Q1 | 44.36 Million SEK | 62.49% |
| 2017 FY | 44.93 Million SEK | 64.59% |
| 2017 Q4 | 44.93 Million SEK | 2.3% |
| 2017 Q3 | 43.92 Million SEK | 24.07% |
| 2016 FY | 27.3 Million SEK | 22.62% |
| 2016 Q4 | 27.3 Million SEK | -17.56% |
| 2016 Q1 | 41 Million SEK | 84.15% |
| 2016 Q3 | 33.11 Million SEK | 2.49% |
| 2016 Q2 | 32.31 Million SEK | -21.19% |
| 2015 Q1 | 30.5 Million SEK | -17.45% |
| 2015 FY | 22.26 Million SEK | -39.74% |
| 2015 Q4 | 22.26 Million SEK | -16.21% |
| 2015 Q3 | 26.57 Million SEK | -12.1% |
| 2015 Q2 | 30.23 Million SEK | -0.9% |
| 2014 Q2 | 22.38 Million SEK | -14.9% |
| 2014 Q4 | 36.95 Million SEK | 90.92% |
| 2014 Q3 | 19.35 Million SEK | -13.55% |
| 2014 FY | 36.95 Million SEK | 26.56% |
| 2014 Q1 | 26.31 Million SEK | -9.89% |
| 2013 Q3 | 13.98 Million SEK | -7.87% |
| 2013 Q4 | 29.19 Million SEK | 108.73% |
| 2013 FY | 29.19 Million SEK | 45.54% |
| 2013 Q1 | 16.48 Million SEK | -17.84% |
| 2013 Q2 | 15.18 Million SEK | -7.87% |
| 2012 FY | 20.06 Million SEK | 54.26% |
| 2012 Q4 | 20.06 Million SEK | 12.95% |
| 2012 Q2 | 19.73 Million SEK | 1.57% |
| 2012 Q3 | 17.76 Million SEK | -10.0% |
| 2012 Q1 | 19.42 Million SEK | 49.4% |
| 2011 Q3 | 14.75 Million SEK | -8.85% |
| 2011 Q4 | 13 Million SEK | -11.88% |
| 2011 Q1 | 17.54 Million SEK | 49.17% |
| 2011 FY | 13 Million SEK | 10.56% |
| 2011 Q2 | 16.19 Million SEK | -7.72% |
| 2010 Q4 | 11.76 Million SEK | -4.35% |
| 2010 Q1 | 14.65 Million SEK | 78.62% |
| 2010 Q2 | 13.69 Million SEK | -6.5% |
| 2010 FY | 11.76 Million SEK | 43.41% |
| 2010 Q3 | 12.29 Million SEK | -10.23% |
| 2009 Q3 | 8.3 Million SEK | -7.19% |
| 2009 FY | 8.2 Million SEK | 48.5% |
| 2009 Q4 | 8.2 Million SEK | -1.27% |
| 2009 Q2 | 8.95 Million SEK | 0.0% |
| 2008 Q4 | 5.52 Million SEK | 0.0% |
| 2008 FY | 5.52 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | 8.204% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 98.244% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 98.244% |
| Arcoma AB | 81.96 Million SEK | 29.571% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 91.547% |
| BICO Group AB (publ) | 10.19 Billion SEK | 99.434% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 92.355% |
| CellaVision AB (publ) | 928.71 Million SEK | 93.784% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -162.918% |
| C-Rad AB (publ) | 404 Million SEK | 85.712% |
| Duearity AB (publ) | 15.14 Million SEK | -281.174% |
| Dignitana AB (publ) | 44.83 Million SEK | -28.761% |
| Episurf Medical AB (publ) | 104.3 Million SEK | 44.655% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.895% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 43.759% |
| Iconovo AB (publ) | 128.07 Million SEK | 54.93% |
| Integrum AB (publ) | 164.85 Million SEK | 64.985% |
| Luxbright AB (publ) | 40.68 Million SEK | -41.877% |
| Mentice AB (publ) | 322.52 Million SEK | 82.102% |
| OssDsign AB (publ) | 356.38 Million SEK | 83.803% |
| Paxman AB (publ) | 167.12 Million SEK | 65.46% |
| Promimic AB (publ) | 92.87 Million SEK | 37.847% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -47.838% |
| SciBase Holding AB (publ) | 64.33 Million SEK | 10.273% |
| ScandiDos AB (publ) | 81.47 Million SEK | 29.148% |
| Sectra AB (publ) | 3.21 Billion SEK | 98.202% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 94.308% |
| Senzime AB (publ) | 433.54 Million SEK | 86.685% |
| SpectraCure AB (publ) | 144.83 Million SEK | 60.144% |
| Stille AB | 804.89 Million SEK | 92.828% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.648% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 97.371% |